Advances in measles virus for cancer therapy / 浙江大学学报·医学版
Journal of Zhejiang University. Medical sciences
; (6): 458-464, 2015.
Article
in Zh
| WPRIM
| ID: wpr-255169
Responsible library:
WPRO
ABSTRACT
Oncolytic virotherapy is a novel cancer therapy. Vaccine-attenuated strains of measles virus(MV)is an ideal candidate for oncolytic virotherapy which has an excellent safety record. Vaccine-attenuated MV uses CD46 and Nectin-4 molecule as major entry receptors into cells. Vaccine-attenuated MV can selectively infect and kill a wide variety of cancer cells in vitro and in vivo. With the development of molecular cloning, scientists have successfully rescued cDNA of vaccine-attenuated MV and increased its oncolytic efficiency with molecular engineering techniques. Phase I clinical trials of virotherapy for ovarian cancer and multiple myeloma with vaccine-attenuated MV are underway. The preliminary results indicate the promising antitumor potential of vaccine-attenuated MV.
Full text:
1
Index:
WPRIM
Main subject:
Therapeutics
/
Clinical Trials, Phase I as Topic
/
Oncolytic Virotherapy
/
Measles virus
/
Neoplasms
Limits:
Humans
Language:
Zh
Journal:
Journal of Zhejiang University. Medical sciences
Year:
2015
Type:
Article